Antibodies to watch in 2014, PMID: 24284914
Antibodies to watch in 2015, PMID: 25484055
Antibodies to watch in 2016, PMID: 26651519
Anti-cytokine biologic treatment beyond anti-TNF in Behçet's disease, PMID: 25268669
Biologic therapy for Behçet's uveitis: a systematic review, PMID: 31676596
Biological treatments in Behçet's disease: beyond anti-TNF therapy, PMID: 25061259
Biologics in the treatment of pustular psoriasis, PMID: 32615817
Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events, PMID: 22571369
Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit?, PMID: 27230767
Current and future treatments for Behçet's uveitis: road to remission, PMID: 23729309
Currently Used Biologic Agents in the Management of Behcet's Syndrome, PMID: 25666786
Cytokines of the IL-1 family: recognized targets in chronic inflammation underrated in organ transplantations, PMID: 28798075
Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties, PMID: 24194526
Effect of Gevokizumab on Interleukin-1β-Mediated Cytochrome P450 3A4 and Drug Transporter Repression in Cultured Human Hepatocytes, PMID: 28260174
Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease, PMID: 25151975
Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes, PMID: 22699287
Emerging therapies for noninfectious uveitis: what may be coming to the clinics, PMID: 24868451
Gevokizumab in the Treatment of Autoimmune Non-necrotizing Anterior Scleritis: Results of a Phase I/II Clinical Trial, PMID: 27663070
Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases?, PMID: 25079039
Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease, PMID: 21154167
Giant Cell Arteritis: Beyond Corticosteroids, PMID: 26239828
Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade, PMID: 26239562
IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives, PMID: 33603750
IL-1β Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus, PMID: 28659798
Inflammasome and cytokine blocking strategies in autoinflammatory disorders, PMID: 23697917
Inhibition of Interleukin-1 in the Treatment of Selected Cardiovascular Complications, PMID: 32674739
Interleukin-1 antagonism in type 1 diabetes of long duration, PMID: 27720360
Interleukin-1 blockade in cardiovascular diseases: a clinical update, PMID: 29584915
Interleukin-1 Blockade in Polygenic Autoinflammatory Disorders: Where Are We now?, PMID: 33708123
Interleukin-1 blockade treatment decreasing cardiovascular risk, PMID: 31415103
Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study, PMID: 22084392
Molecule of the month. XOMA-052, PMID: 20016858
One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β, PMID: 23041424
One year in review 2016: Behçet's syndrome, PMID: 27791958
Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases, PMID: 28588486
Rheumatoid Arthritis Associated Episcleritis and Scleritis: An Update on Treatment Perspectives, PMID: 34068884
Safety and Efficacy of Gevokizumab in Patients with Behçet's Disease Uveitis: Results of an Exploratory Phase 2 Study, PMID: 26829647
Targeting inflammation in diabetic kidney disease: early clinical trials, PMID: 27268955
Targeting Interleukin-1 beta to Suppress Sympathoexcitation in Hypothalamic Paraventricular Nucleus in Dahl Salt-Sensitive Hypertensive Rats, PMID: 26304161
The challenge of autoinflammatory syndromes: with an emphasis on hyper-IgD syndrome, PMID: 27856657
The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure, PMID: 30062160
The interleukin-1β modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model, PMID: 25108619
The right place of interleukin-1 inhibitors in the treatment of Behçet's syndrome: a systematic review, PMID: 30799530
The Use of Biologic Therapies in Uveitis, PMID: 25431348
Treatment of Inflammatory Diseases with IL-1 Blockade, PMID: 33133777
Treatment of two patients with generalized pustular psoriasis with the interleukin-1β inhibitor gevokizumab, PMID: 25495649
Update on the use of systemic biologic agents in the treatment of noninfectious uveitis, PMID: 24600203
Use of Gevokizumab in Patients with Behçet's Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study, PMID: 29370572
Which are the antibodies to watch in 2013?, PMID: 23254906
XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases, PMID: 21048425
A Meta-Analysis Methodology in Stan to Estimate Population Pharmacokinetic Parameters from Multiple Aggregate Concentration-Time Datasets: Application to Gevokizumab mPBPK Model., PMID:39339167
Identification of critical genes and metabolic pathways in rheumatoid arthritis and osteoporosis toward drug repurposing., PMID:39079412
Efficacy and safety of envafolimab in the treatment of advanced dMMR/MSI‑H solid tumors: A single‑arm meta‑analysis., PMID:37545619
Targeting the IL1β Pathway for Cancer Immunotherapy Remodels the Tumor Microenvironment and Enhances Antitumor Immune Responses., PMID:37040466
Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders., PMID:35874710
Current treatment options for monogenic periodic fever syndromes - the role of interleukin 1 inhibitors., PMID:35354288
Rheumatoid Arthritis Associated Episcleritis and Scleritis: An Update on Treatment Perspectives., PMID:34068884
Interleukin-1 Blockade in Polygenic Autoinflammatory Disorders: Where Are We now?, PMID:33708123
IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives., PMID:33603750
Inhibition of Interleukin-1 in the Treatment of Selected Cardiovascular Complications., PMID:32674739
Biologics in the treatment of pustular psoriasis., PMID:32615817
Biologic therapy for Behçet's uveitis: a systematic review., PMID:31676596
Interleukin-1 blockade treatment decreasing cardiovascular risk., PMID:31415103
Targeting blockade of nuclear factor-κB in the hypothalamus paraventricular nucleus to prevent cardiac sympathetic hyperinnervation post myocardial infarction., PMID:31175933
The right place of interleukin-1 inhibitors in the treatment of Behçet's syndrome: a systematic review., PMID:30799530
Microglial Mincle receptor in the PVN contributes to sympathetic hyperactivity in acute myocardial infarction rat., PMID:30353660
The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure., PMID:30062160
Interleukin-1 blockade in cardiovascular diseases: a clinical update., PMID:29584915
Use of Gevokizumab in Patients with Behçet's Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study., PMID:29370572
Treatment of Inflammatory Diseases with IL-1 Blockade., PMID:33133777
Cytokines of the IL-1 family: recognized targets in chronic inflammation underrated in organ transplantations., PMID:28798075
IL-1β Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus., PMID:28659798
Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases., PMID:28588486
Effect of Gevokizumab on Interleukin-1β-Mediated Cytochrome P450 3A4 and Drug Transporter Repression in Cultured Human Hepatocytes., PMID:28260174
The challenge of autoinflammatory syndromes: with an emphasis on hyper-IgD syndrome., PMID:27856657
One year in review 2016: Behçet's syndrome., PMID:27791958
Interleukin-1 antagonism in type 1 diabetes of long duration., PMID:27720360
Gevokizumab in the Treatment of Autoimmune Non-necrotizing Anterior Scleritis: Results of a Phase I/II Clinical Trial., PMID:27663070
Targeting inflammation in diabetic kidney disease: early clinical trials., PMID:27268955
Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit?, PMID:27230767
Safety and Efficacy of Gevokizumab in Patients with Behçet's Disease Uveitis: Results of an Exploratory Phase 2 Study., PMID:26829647
Antibodies to watch in 2016., PMID:26651519
Targeting Interleukin-1 beta to Suppress Sympathoexcitation in Hypothalamic Paraventricular Nucleus in Dahl Salt-Sensitive Hypertensive Rats., PMID:26304161
Giant Cell Arteritis: Beyond Corticosteroids., PMID:26239828
Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade., PMID:26239562
Currently Used Biologic Agents in the Management of Behcet's Syndrome., PMID:25666786
Treatment of two patients with generalized pustular psoriasis with the interleukin-1β inhibitor gevokizumab., PMID:25495649
Antibodies to watch in 2015., PMID:25484055
The Use of Biologic Therapies in Uveitis., PMID:25431348
Anti-cytokine biologic treatment beyond anti-TNF in Behçet's disease., PMID:25268669
Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease., PMID:25151975
The interleukin-1β modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model., PMID:25108619
Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases?, PMID:25079039
Biological treatments in Behçet's disease: beyond anti-TNF therapy., PMID:25061259
Emerging therapies for noninfectious uveitis: what may be coming to the clinics., PMID:24868451
Update on the use of systemic biologic agents in the treatment of noninfectious uveitis., PMID:24600203
Antibodies to watch in 2014., PMID:24284914
Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties., PMID:24194526
Current and future treatments for Behçet's uveitis: road to remission., PMID:23729309
Inflammasome and cytokine blocking strategies in autoinflammatory disorders., PMID:23697917
For research use only. Not for human or drug use.
